Healthcare Business Recap: Rosetta Shares POP, Johnson & Johnson PARTNERS With Glaxo

Shares of Rosetta Genomics Ltd. (NASDAQ:ROSG) gained a third of their value on Thursday, subsequent Aegis Capital’s initiation coverage with a Buy plus a price target of $16. The stocks had notably spiked on Monday as well, on word of new management hires.

Don’t Miss: Hain Celestial Earnings: Investors Taste GOOD News.

Johnson & Johnson (NYSE:JNJ) division Janssen Biologics said that it has started the Phase 3 development program for sirukumab as part of a collaboration with GlaxoSmithKline (NYSE:GSK). The drug is a human anti-interleukin-6 monoclonal antibody which is being evaluated for the treatment of adults who suffer from moderately to severely active rheumatoid arthritis.

The FDA is said to have okayed the genetic version developed by Akorn, Inc. (NASDAQ:AKRX) of Allergan’s (NYSE:AGN) Alocril, which is a prescription eye drop for itching allergy-beset eyes.

Don’t Miss: Why are Facebook Founders DUMPING Shares?

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.